Curve Biosciences, the Whole-Body Intelligence company, announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others.

Health Technology Insights: Lyric Health, Curaechoice Partner for Free Virtual Care

The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring.

Curve has created the first molecular blueprint of the human body with the company’s Whole-Body Atlas — the world’s largest collection of manually curated tissue samples characterized by organ and disease state. By returning to tissue-level biological truth, the company is creating simple, proactive Whole-Body Blood Tests that anticipate chronic disease, guide treatment, and align patients, insurers, pharma, and doctors.

“Chronic diseases are on the rise, and healthcare costs are skyrocketing as a result. We need to improve patient monitoring to realize the positive impacts of breakthroughs like GLP-1s,” said Ritish Patnaik, PhD, CEO and Co-Founder, Curve Biosciences. “To raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests. We’ve paired this platform with a successful executive team to realize our vision for proactive, personalized chronic care that minimizes suffering.”

Health Technology Insights: Samsung Health and HealthTap Expand Access to Virtual Primary Care to Millions

Curve’s executive team includes:

  • Ritish Patnaik, PhD, Chief Executive Officer – Former business development at Genentech, with deep expertise in AI, data engineering and precision testing.
  • Nathan Hunkapiller, PhD, Chief Scientific Officer – Previously Head of R&D at Natera and Head of R&D at GRAIL, where he led the development of advanced blood tests for oncology, prenatal screening and hereditary cancer screening.
  • Alice Chen, PhD, Chief Operating Officer – Former Head of Product and Program Management at GRAIL, where she led strategy for a multi-cancer early detection blood test, after leadership roles at Natera, Progyny and Sienna Biopharmaceuticals.
  • Chuba Oyolu, PhD, Chief Technology Officer – Founding Scientist and Senior Site Director at Counsyl, where he led the automation, delivery, and scaling of advanced blood tests for prenatal screening and hereditary cancer screening.
  • Prof. Shan Wang, PhD, Chief Innovation Officer and Scientific Founder – Leland T. Edwards Professor in the School of Engineering at Stanford University with 300+ publications and 70+ issued or pending patents over his 30+ year academic career.

The company will provide further information on its Whole-Body Intelligence platform and chronic disease pipeline in the upcoming months.

“We believe Curve’s Whole-Body Intelligence platform represents the next frontier in clinical testing, with the potential to fundamentally reshape how we monitor and manage chronic disease,” said Themasap Khan, PhD, Co-Founder and Partner, Luma Group. “By anchoring in human tissue data, Curve is building a clinically actionable platform with clear reimbursement potential and massive market applicability.”

Health Technology Insights: Lirio Launches Behavioral Science Patient Engagement Tool

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com

Source – businesswire